Locally Advanced Pancreatic Cancer Clinical Trials

10 recruiting

Locally Advanced Pancreatic Cancer Trials at a Glance

11 actively recruiting trials for locally advanced pancreatic cancer are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Not Applicable with 4 trials, with the heaviest enrollment activity in Washington D.C., Baltimore, and Bergen. Lead sponsors running locally advanced pancreatic cancer studies include Fujian Provincial Hospital, Institute of Oncology Ljubljana, and Du Juan.

Browse locally advanced pancreatic cancer trials by phase

Treatments under study

About Locally Advanced Pancreatic Cancer Clinical Trials

Looking for clinical trials for Locally Advanced Pancreatic Cancer? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Locally Advanced Pancreatic Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Locally Advanced Pancreatic Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 2

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Endometrial CancerLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm+10 more
Rahul Aggarwal89 enrolled3 locationsNCT03682289
Recruiting
Phase 2

A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer

Locally Advanced Pancreatic Cancer With KRAS G12D Mutation
The First Affiliated Hospital with Nanjing Medical University30 enrolled1 locationNCT07438106
Recruiting
Phase 1Phase 2

Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)

Locally Advanced Pancreatic Cancer
University of Maryland, Baltimore24 enrolled2 locationsNCT03652428
Recruiting
Not Applicable

Combined Chemotherapy And Ablative Radiotherapy (SBRT) As First-Line Treatment In Locally Advanced Inoperable Pancreatic Cancer (SBRT-PANC)

Locally Advanced Pancreatic Cancer
Institute of Oncology Ljubljana18 enrolled1 locationNCT07407231
Recruiting
Phase 3

Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

Locally Advanced Pancreatic Cancer
RenovoRx190 enrolled42 locationsNCT03257033
Recruiting
Not Applicable

MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial

Pancreatic CancerCervical CancerLocally Advanced Cervical Carcinoma+7 more
Washington University School of Medicine60 enrolled1 locationNCT05975593
Recruiting
Not Applicable

Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer

Locally Advanced Pancreatic CancerIrreversible Electroporation
University of Saskatchewan27 enrolled2 locationsNCT04276857
Recruiting

A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer

Chemotherapy EffectLocally Advanced Pancreatic CancerPancreatectomy+1 more
Oslo University Hospital400 enrolled5 locationsNCT06944587
Recruiting
Phase 3

Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer

Locally Advanced Pancreatic Cancer
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd512 enrolled5 locationsNCT05653453
Recruiting
Phase 1Phase 2

mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer

Metastatic Pancreatic CancerLocally Advanced Pancreatic Cancer
Fujian Provincial Hospital29 enrolled4 locationsNCT06761027
Recruiting
Not Applicable

NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer

Locally Advanced Pancreatic Cancer
Du Juan40 enrolled2 locationsNCT06494514